The estimated Net Worth of Timothy B Anderson is at least $936 Mille dollars as of 1 June 2021. Mr. Anderson owns over 13,228 units of Cerus stock worth over $438,686 and over the last 21 years he sold CERS stock worth over $326,882. In addition, he makes $170,434 as Independent Director at Cerus.
Timothy has made over 16 trades of the Cerus stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 13,228 units of CERS stock worth $27,117 on 1 June 2021.
The largest trade he's ever made was exercising 50,000 units of Cerus stock on 18 May 2018 worth over $151,500. On average, Timothy trades about 8,108 units every 150 days since 2004. As of 1 June 2021 he still owns at least 213,993 units of Cerus stock.
You can see the complete history of Mr. Anderson stock trades at the bottom of the page.
Timothy Bruce Anderson serves as Independent Director of the Company. Mr. Anderson was Senior Vice President of Strategy and Business Development of Baxter International, Inc., a pharmaceutical company, from 1999 until 2002, and held various management positions at Baxter International from 1992 until 1999, including President, Biotech Group from 1992 until 1997, Group Vice President from 1993 until 1997 and Chairman, Baxter Europe from 1997 until 1999. From 2006 until 2010, Mr. Anderson served as a member of the board of directors of Puricore Public Limited Company.
As the Independent Director of Cerus, the total compensation of Timothy Anderson at Cerus is $170,434. There are 9 executives at Cerus getting paid more, with William Greenman having the highest compensation of $3,270,180.
Timothy Anderson is 73, he's been the Independent Director of Cerus since 2003. There are 1 older and 12 younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
Timothy's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash e Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: